• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Paulson defends Ackman, buys 1B of AGN stock


<







It's like shooting fish in a barrel, it takes a bit of time but eventually they will die. The leaders will make a lot of money on the way out, don't feel bad for them